A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

NCT ID: NCT03057171

Last Updated: 2019-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Helicobacter pylori (H.pylori) is a major human pathogenic bacterium in gastric mucosa which is linked to the development of gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. However the regulatory mechanism of H.pylori-induced immune response is not clear. Long non-coding RNA (lncRNA) has recently emerged as key post-transcriptional regulators of gene expression, differentiation. The investigators had a preliminary results which THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) and PACER(p50-associated COX-2 extragenic RNA) played a potential role in H.pylori induced inflammatory cascade. However, there wasn't a previous study about expression of THRIL, PACER in a human tissue. Therefore, the investigators aimed to evaluate the expression of THRIL, PACER in patients with gastrointestinal disease according to H.pylori infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Infection Gastric Ulcer Duodenal Ulcer Stomach Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gastric ulcer

patients who will undergo EGD for gastric ulcer

No interventions assigned to this group

Duodenal ulcer

patients who will undergo EGD for duodenal ulcer

No interventions assigned to this group

Stomach cancer

patients who will undergo EGD for stomach cance

No interventions assigned to this group

health individuals

patients who will undergo screening EGD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over 19 years old
2. Patients with gastric ulcer
3. Patients with duodenal ulcer
4. Patients with stomach cancer
5. Patients with gastrointestinal discomfort symptoms

Exclusion Criteria

1. Patients who has done helicobacter pylori eradication
2. Patients who has undergone gastrectomy
3. Patients who has undergone endoscopic submucosal dissection
4. Patients with active upper gastrointestinal bleeding
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yonsei university College of Medicine

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sang Kil Lee, MD

Role: CONTACT

82-2-2228-1996

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sang Kil Lee, MD

Role: primary

82-2-2228-1996

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2015-0146

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.